PBH
Prestige Consumer Healthcare Inc.
PBH's fundamentals are mixed: it turned 18% of its revenue into free cash flow, but its operating margin fell 5 points to 25%. At 14x earnings, it's trading in line with its usual 15x. Analysts expect earnings growth.
PBH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
PBH's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
PBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.5x | $45.32 | — |
| Cheap | 13x | $41.99 | -7.4% |
| Current | 14x | $45.32 | — |
| Fair | 15x | $48.52 | +7.1% |
| Expensive | 18x | $57.31 | +26% |
Historical ranges are pointers, not guarantees.
PBH's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
PBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PBH, but weaker profitability.
PBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.78 | +48% |
| Q3 2026 | $3.24 | -20% |
| Q2 2026 | $3.57 | -16% |
| Q1 2026 | $3.91 | -8.9% |
| Q4 2025 | $3.78 | -11% |
| Q3 2025 | $4.03 | -1.9% |
| Q2 2025 | $4.26 | +4.2% |
| Q1 2025 | $4.29 | +2.9% |
| Q4 2024 | $4.27 | +$5.88 |
PBH earned $3.24 per share over the past year, down 20% from the year before.
PBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $336.3M | +23% |
| Q2 2026 | $265.7M | +6.5% |
| Q1 2026 | $281.6M | -5% |
| Q4 2025 | $283.4M | -2.4% |
| Q3 2025 | $274.1M | -3.4% |
| Q2 2025 | $249.5M | -6.6% |
| Q1 2025 | $296.5M | +7% |
| Q4 2024 | $290.3M | +2.7% |
PBH's revenue has picked up after four years of holding roughly level: $336M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.1 points |
| Q2 2026 | 20% | -9 points |
| Q1 2026 | 27% | -3 points |
| Q4 2025 | 29% | -2.6 points |
| Q3 2025 | 29% | -0.7 points |
| Q2 2025 | 29% | +1.8 points |
| Q1 2025 | 30% | +0.2 points |
| Q4 2024 | 32% | +1 points |
PBH's operating margin was 24% last quarter, down 5.1 points from the same quarter a year ago, near the bottom of its range since 2019.
PBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.2M | -38% |
| Q2 2026 | $67.1M | -14% |
| Q1 2026 | $37.6M | -36% |
| Q4 2025 | $75.3M | +18% |
| Q3 2025 | $55.4M | -18% |
| Q2 2025 | $78.2M | +46% |
| Q1 2025 | $58.4M | -8.5% |
| Q4 2024 | $63.5M | -8.6% |
PBH's free cash flow has been positive every quarter for seven years: $214M over the past year, down 16% from the year before.
PBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11K shares |
| 1 year | -3.4% | -1.7M shares |
| 3 years | -5% | -2.5M shares |
| 5 years | -6.3% | -3.2M shares |
| Available history | -6.4% | -3.2M shares |
PBH has 48M diluted shares, down 3.4% from a year ago, with $47M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $690,000 |
| Q4 2025 | $45.8M |
| Q3 2025 | $75M |
| Q2 2025 | $34.8M |
| Q1 2025 | $11.3M |
| Q4 2024 | $2.4M |
PBH spent $47M buying back its own shares over the past year, down 62% from the year before.
PBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.2x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 2.6x | Moderate |
PBH's net debt is about 6.2 years of its operating earnings (EBITDA), up from 2.4 years a year ago.
PBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 25.2 | Neutral |
PBH's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
PBH PE vs Healthcare Sector
| Metric | PBH | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 46% below |
| PE % | 29 | 29 | Same percentile |
PBH is trading at 14x earnings, a 46% discount to the Healthcare sector's median of 26x.
PBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 3.4% below |
| 20 week MA | $48.9 | 7.3% below |
| 50 week MA | $54.7 | 17% below |
| 100 week MA | $65.0 | 30% below |
| 200 week MA | $65.3 | 31% below |
PBH is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
PBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $34.9 | -14% |
| 2021 | $34.9 | $61.9 | +77% |
| 2022 | $61.9 | $62.0 | +0.2% |
| 2023 | $62.0 | $61.2 | -1.3% |
| 2024 | $61.2 | $78.5 | +28% |
| 2025 | $78.5 | $62.8 | -20% |
| 2026 YTD | $62.8 | $45.3 | -28% |
PBH has finished lower in three of the last six years. It's down 28% so far in 2026.